Source - RNS
RNS Number : 3001P
Integumen PLC
07 February 2019
 

 

 

 

("Integumen" or "the Company")

 

Changes to interests of a significant shareholder

 

Integumen plc (AIM: SKIN), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM Rule 17, the following details are now notified:

 

a)   Identity of the significant shareholder: Helium Rising Stars Fund

 

b)   Date of disclosure: 6 February 2019

 

c)   Date of relevant change: 5 February 2019

 

d)   Price, amount and class: 21,240,415 ordinary shares of 0.01p each; price not disclosed

 

e)   Nature of transaction: purchase of shares

 

f)    Nature and extent of significant shareholder's interest: direct and indirect interests

 

g)   Resultant shareholding: 42,762,295 shares, with a direct interest in the shares and an indirect interest in the voting rights, in each case amounting to 9.40%

 

In compliance with DTR5, a copy of the notification received from this investor is appended.

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP (Broker)

Claire Noyce

+44 (0) 20 3764 2341

 

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

 

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

TR-1: Standard form for notification of major holdings

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Integumen Plc

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Helium Rising Stars Fund

City and country of registered office (if applicable)

Cayman Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

05/02/2019

6. Date on which issuer notified (DD/MM/YYYY):

06/02/2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.40%

 

9.40%

         454'826'872      

Position of previous notification (if

applicable)

8.57%

 

8.57%

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

(Art 9 of Directive 2004/109/EC) (DTR5.1)

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

(Art 9 of Directive 2004/109/EC) (DTR5.1)

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYWJ6269

               

               

42'762'295

 

 

 

9.40%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

42'762'295

9.40%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

                   

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

 

Namexv

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

         

 

Place of completion

Zürich, Switzerland

Date of completion

06/02/2019

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKADQABKDQBK